|
|
Application Status and Evaluation of Combination Vaccines |
REN Jun,LI Jian-min,CHEN Wei |
Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogens and Biosecurity, Beijing 100071, China |
|
|
Abstract A combination vaccine which consists of ≥2 immunogens is intended to provide protection against two or more diseases or against multiple serotypes of a single disease. The use of combination vaccines decrease the number of vaccine injections in the regular immunization schedules. However,the development of combination vaccines is more complicated than monovalent vaccines, preservatives and adjuvants used with one component may alter the potency of other components. Physical, chemical, and biological interactions between the components of combination vaccines must be considered to avoid detrimental effects on safety or efficacy. Therefore combination vaccines present unique challenges for product evaluation. This paper presents a review of research application status, the evaluation of effectiveness and safety, as well as development prospects on combination vaccines.
|
Received: 27 February 2009
Published: 07 December 2009
|
|
|
|
[1] |
Ryman T K, Dietz V, Cairns K L. Too little but not too late: results of a literature review to improve routine immunization programs in developing countries. BMC Health Serv Res. 2008, 8:134
|
|
|
[2] |
Murphy T V, Slade B A, Broder K R, et al. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP) . MMWR Recomm Rep, 2008, 57(RR4):1~51
|
|
|
[3] |
Mallet E, Belohradsky B H, Lagos R, et al. A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety. Vaccine, 2004, 22 (1112):1343~1357
|
|
|
[4] |
Centers for Disease Control and Prevention (CDC). Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and haemophilus B conjugate vaccine and guidance for use in infants and children. MMWR Morb Mortal Wkly Rep, 2008, 57(39):1079,1080
|
|
|
[5] |
刘大卫,郭飚,曹玲生,等. 吸附无细胞和全细胞百白破联合疫苗上市后预防接种安全性的比较分析.中国疫苗和免疫,2008,14(2):97~102 Liu D W, Guo B, Cao L S, et al. Chinese Journal of Vaccines and Immunization, 2008, 14(2):97~102
|
|
|
[6] |
Stokes J J, Weibel R E, Villarejos V M, et al.Trivalent combined measlesmumpsrubella vaccine. Findings in clinicallaboratory studies. JAMA, 1971, 218(1):57~61
|
|
|
[7] |
Gillet Y, Steri G C, Behre U, et al. Immunogenicity and safety of measlesmumpsrubellavaricella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months2 years or 2~6 years primed with measlesmumpsrubella (MMR) vaccine. Vaccine, 2009, 27(3):446~453
|
|
|
[8] |
何奔, 林云, 王金荣, 等. 国产麻疹、流行性腮腺炎、风疹疫苗免疫效果观察. 实用预防医学, 2008, 15(4):1111~1112 He B, Lin Y, Wang J R, et al. Practical Preventive Medicine, 2008, 15(4):1111,1112
|
|
|
[9] |
Beran J. Ten year’s experience with combined hepatitis A and B vaccine . Klin Mikrobiol Infekc Lek, 2008, 14(1):13,14, 16~23
|
|
|
[10] |
Joines R W, Blatter M, Abraham B, et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and EngerixB) in adults. Vaccine, 2001, 19(32): 4710~4719
|
|
|
[11] |
万宗举, 张华远, 梁争论, 等. 倍尔来福TM甲乙型肝炎联合疫苗在成人中应用的安全性和免疫原性研究. 中国计划免疫,2004,10(3):129~132 Wan Z J,Zhang H Y, Liang Z L, et al. The Chinese Journal of Vaccines and Immunization, 2004, 10(3):129~132
|
|
|
[12] |
Griffin K, Bedford R, Townson K, et al. Protective efficacy of a recombinant plague vaccine when coadministered with another subunit or live attenuated vaccine .FEMS Immunol Med Microbiol, 2005,43(3): 425~430
|
|
|
[13] |
Morefield G L, Tammariello R F, Purcell B K, et al. An alternative approach to combination vaccines: intradermal administration of isolated components for control of anthrax, botulism, plague and staphylococcal toxic shock. J Immune Based Ther Vaccines, 2008, 6:5
|
|
|
[14] |
Elliman D, Bedford H. Safety and efficacy of combination vaccines . BMJ, 2003, 326(7397):995,996
|
|
|
[15] |
Wakefield A J, Murch S H, Anthony A, et al. Ileallymphoidnodular hyperplasia, nonspecific colitis, and pervasive developmental disorder in children. Lancet, 1998, 351(9103): 637~641
|
|
|
[16] |
Hornig M, Briese T, Buie T, et al. Lack of association between measles virus vaccine and autism with enteropathy: a casecontrol study. PLoS ONE, 2008, 3(9):e3140
|
|
|
[17] |
Mikaeloff Y, Caridade G, Rossier M, et al. Hepatitis B vaccination and the risk of childhoodonset multiple sclerosis. Arch Pediatr Adolesc Med, 2007, 161(12):1176~1182
|
|
|
[18] |
Offit P A, Quarles J, Gerber M A, et al. Addressing parents’ concerns: do multiple vaccines overwhelm or weaken the infant’s immune system. Pediatrics, 2002, 109(1):124~129
|
|
|
[19] |
Taffs R E. Potency tests of combination vaccines. Clin Infect Dis. 2001, 33(4):S362~S366
|
|
|
[20] |
Guerra F A, Blatter M M, Greenberg D P, et al. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial. Pediatrics, 2009, 123(1):301~312
|
|
|
[21] |
Cuervo M L, Sterling A L, Nicot I A, et al. Validation of a new alternative for determining in vitro potency in vaccines containing Hepatitis B from two different manufacturers . Biologicals, 2008, 36(6): 375~382
|
|
|
[22] |
Story C M, Papa E, Hu C C, et al. Profiling antibody responses by multiparametric analysis of primary B cells. Proc Natl Acad Sci USA, 2008, 105(46):17902~17907
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|